H Logo

Advanced Research Projects Agency for Health (ARPA-H) has recently opened its first Agency-wide Open Broad Agency Announcement (BAA), which seeks funding proposals for research to improve health outcomes across patient populations, communities, diseases, and health conditions. The BAA calls for proposals that outline breakthrough research and technological advancements, investigate unconventional approaches, and challenge accepted assumptions to enable leaps forward in science, technology, systems, or related capabilities. ARPA-H also encourages concepts that advance the objectives of President Biden's Cancer Moonshot initiative, as well as more disease-agnostic approaches.​

Https cdn evbuc com images 459332189 249939156208 1 original

Join us for a lunch and learn to hear how new technologies in quantum computing will be utilized to power scientific research and the life science companies already taking advantage. Shahar Keinan, CEO, and Maurice Benson, Lead Software Engineer at POLARISqb, will give a presentation on how the innovations in the quantum computing industry will directly impact the future of drug design, clinical research, and precision medicine. POLARISqb has created one of the first platforms for the life sciences industry that can cut the drug discovery research process timeline from its traditional time of 5 years down to 4 months. Shahar and Maurice will also discuss how quantum computers are beginning to be made ready for commercial use and all of the recent case studies on their performance.

Image: https://www.eventbrite.com

Giorgio Trovato/Unsplash, Jesse Bowser/Unsplash

The tragic and shocking demise of SVB and bailout of its depositors is a watershed, “Too Big to Fail” event for Silicon Valley that will reverberate for years to come, if not longer, bringing significant new challenges to the industry in both the short and long term.

For the small but critically important world of startups and venture capital, things have gone from bad to worse. After a year of upheaval—plummeting stock valuations, dormant M&A and IPO markets, and massive layoffs—the tech industry now bears the indignity of losing a cherished institution that nearly sparked a national financial panic.

Image: Giorgio Trovato/Unsplash, Jesse Bowser/Unsplash

Untitled design 41

The collapse of Silicon Valley Bank (SVB) on Friday, March 10, sent shockwaves through the tech and biotech world. But it does not appear to have had a major effect on the BioHealth Capital Region and the Philadelphia region’s life sciences industry, at least not so far.

On about March 8, SVB, a major supporter of tech, biotech and venture capital funds, indicated it was facing a cashflow problem. Initially, it attempted to raise money by selling shares. Then it attempted to sell itself. Investors were alarmed by these efforts and began pulling their funds from the bank, causing a run on the bank, leading to shares plunging on Thursday, March 9. On Friday, March 10, regulators shut down the bank.

Image: https://biobuzz.io/


FREDERICK, Md., March 13, 2023 /PRNewswire-PRWeb/ -- RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, development services, cell engineering, and advanced therapy bioprocess solutions, today announced that it has selected Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, as a collaboration partner to advance scalable exosome bioprocessing.

RoosterBio's goal, in collaboration with Repligen, is to deliver solutions for manufacturing of exosomes using scalable and low shear technologies that enable cost-effective commercialization of these advanced therapies.

Seth and Rich Gif

Want to be on the cutting edge of disease treatment? Learn how companies like Immunyx Pharma are changing the landscape of immune modulation in the battle against diseases with the JLABS/BARDA Blue Knight program on this episode of BioTalk with Rich Bendis.

Also Available on popular podcast platforms like Apple https://apple.co/3LlbxIy, Google https://bit.ly/3l6O6ba, Spotify https://spoti.fi/405ln5B, Amazon Music https://amzn.to/3J58kde, TuneIn https://bit.ly/3JA8MBO, and even YouTube https://bit.ly/3LhYZS6.


LEIDEN, the Netherlands, March 07 / B3C newswire / -- MIMETAS, a leading company in the field of organ-on-a-chip-based disease models, announces that it has launched its Adult Stem Cell (ASC)-derived tubular organoids in an assay-ready format. As part of its OrganoReady® product line, MIMETAS offers two organoid-based products: ASC-derived Colon1 and Kidney2 Organoid tubules.

“We are thrilled to offer this cutting-edge technology to the research community,” says Jos Joore, co-CEO of MIMETAS. “We’ve worked for several years to optimize these OrganoReady® organoid products. As a result, our early-access users will be the first in the world to have license-free access to ready-to-use, donor-relevant organoid tubules of consistent quality.”

Artificial intelligence 2022 11 11 06 07 32 utc

In the field of artificial intelligence, there are winters and there are springs—barren stretches followed by exhilarating bursts of innovation and funding. Right now, we find ourselves definitively in the midst of an AI spring, says Johns Hopkins engineer Rama Chellappa, a veteran of the industry for more than four decades.



ROCKVILLE, MARYLAND, March 8, 2023 BioHealth Innovation Inc. (BHI) is pleased to welcome Mona Suliman, Ph.D., as a new Life Sciences Business Strategist. In this role, Mona will evaluate the commercial potential of clients’ emerging technologies and assist start-ups with their go-to-market strategies. Her work will also focus on helping biohealth companies to secure non-dilutive funding.

Mona Suliman has been a consultant in the business and science sectors for over eight years. Her specific areas of focus are entrepreneurship, innovation, strategy, and marketing. She obtained her Master’s in Business Administration from George Mason University and her Ph.D. in Biochemistry from Virginia Commonwealth University in Richmond. As a consultant, she supported companies in developing marketing strategies and creating product launch plans and development strategies.

“We are thrilled to welcome Mona to BHI,” said Richard Bendis, BHI President, and CEO. “I am confident Mona will bring a unique perspective and energy to our team and BioHealth Partners.”

About BioHealth Innovation, Inc. 

BioHealth Innovation, Inc. (BHI) is a public-private nonprofit organization focused on accelerating biohealth (therapeutic, diagnostic, medtech, and health IT) commercialization in the BioHealth Capital Region (Maryland, DC, and Virginia).


# # #

Media contacts:
Rich Bendis
Phone: 301-637-6439, email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Lucy and Rich Gif

Lucy Alexander, Capabilities Lead, Global Supply Chain & Strategy with AstraZeneca, joins Rich Bendis on BioTalk to discuss leading world-class supply chain operations, developing new strategies, and the continued growth of AZ in the BioHealth Capital Region.

Listen via Apple https://apple.co/3Zov7b7, Google https://bit.ly/3JfYiav, Spotify https://spoti.fi/3ZGPekn, Amazon Music https://amzn.to/3ZqknsP, and TuneIn http://bit.ly/2M60Wmx.

Sarah Miller, MS

The BioHealth Innovation, Inc. (BHI) team would like to extend its deepest gratitude to Sarah Miller, Vice President of Economic Development, for her invaluable contributions to the organization as she moves on to a new opportunity. Sarah has played an integral role in BHI's mission to accelerate the commercialization of BioHealth technologies and worked tirelessly to build and maintain strong relationships with industry stakeholders and partners. Her dedication and hard work will be greatly missed, and we wish her all the best in her future endeavors.

SGID SW View V2 labeled

The Shady Grove Innovation District is a planned mixed-use, transit-served innovation ecosystem of more than 1.3M SF located in Maryland’s premier life sciences cluster.

BXP, formerly Boston Properties, recently unveiled plans at its pre-application community meeting to develop the Shady Grove Innovation District (“SGID”), a world-class, amenity-rich, mixed-use district catering to the dynamic life science industry in the heart of the Shady Grove cluster in Rockville, Maryland.  SGID will initially include 150,000 square feet of lab/R&D space in a five-story building and 315 luxury apartments. The district has the potential to grow to more than 1.3M square feet of lab/R&D space across a total of nine buildings.  Construction could begin as early as mid-2024.